Syrrx

Syrrx

Combines high-throughput structure determination, HTS, combinatorial and medicinal chemistry together with computational methods to discover novel small molecule drug candidates and thereby perform truly high-throughput rational drug discovery. Syrrx was acquired by Takeda (NASDAQ:TPNA).

< Back to Portfolios